Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Tsuji

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Clinical Pharmacology and Therapeutics|December 8, 2023
Machine Learning-Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram-Negative BacteriaNicholas M Smith, Thomas D Nguyen, Thomas P Lodise, et al.
Antimicrobial Agents and Chemotherapy|December 18, 2013
New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver diseaseGauri G Rao, Neang S Ly, Curtis E Haas, et al.
Antimicrobial Agents and Chemotherapy|February 8, 2017
New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniaeZackery P Bulman, Michael J Satlin, Liang Chen, et al.
Antimicrobial Agents and Chemotherapy|April 13, 2016
Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiBrian T Tsuji, Cornelia B Landersdorfer, Justin R Lenhard, et al.
The Lancet. Infectious Diseases|December 3, 2014
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensusRoger L Nation, Jian Li, Otto Cars, et al.
The Journal of Antimicrobial Chemotherapy|April 27, 2017
Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniaeMiao Zhao, Zackery P Bulman, Justin R Lenhard, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant <i>Klebsiella pneumoniae</i>Jan Naseer Kaur, Jack F Klem, Gebremedhin S Hailu, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activityJustin R Lenhard, Visanu Thamlikitkul, Fernanda P Silveira, et al.
The Journal of Antimicrobial Chemotherapy|August 6, 2016
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategiesGauri G Rao, Neang S Ly, Jürgen B Bulitta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 11, 2013
Consistent global approach on reporting of colistin doses to promote safe and effective useRoger L Nation, Jian Li, Otto Cars, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|December 8, 2023
Machine Learning-Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram-Negative BacteriaNicholas M Smith, Thomas D Nguyen, Thomas P Lodise, et al.
Antimicrobial Agents and Chemotherapy|December 18, 2013
New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver diseaseGauri G Rao, Neang S Ly, Curtis E Haas, et al.
Antimicrobial Agents and Chemotherapy|February 8, 2017
New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniaeZackery P Bulman, Michael J Satlin, Liang Chen, et al.
Antimicrobial Agents and Chemotherapy|April 13, 2016
Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiBrian T Tsuji, Cornelia B Landersdorfer, Justin R Lenhard, et al.
The Lancet. Infectious Diseases|December 3, 2014
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensusRoger L Nation, Jian Li, Otto Cars, et al.
The Journal of Antimicrobial Chemotherapy|April 27, 2017
Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniaeMiao Zhao, Zackery P Bulman, Justin R Lenhard, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-Resistant <i>Klebsiella pneumoniae</i>Jan Naseer Kaur, Jack F Klem, Gebremedhin S Hailu, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activityJustin R Lenhard, Visanu Thamlikitkul, Fernanda P Silveira, et al.
The Journal of Antimicrobial Chemotherapy|August 6, 2016
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategiesGauri G Rao, Neang S Ly, Jürgen B Bulitta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 11, 2013
Consistent global approach on reporting of colistin doses to promote safe and effective useRoger L Nation, Jian Li, Otto Cars, et al.
Pageof 11